Evidence map›Paper›PMID 42499270›Full record

Trial reportPediatric blood & cancer2026

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials.

Willem H Collier, Mark Zobeck, Adam J Esbenshade, Christopher C Dvorak, Lillian Sung, David Freyer, Sarah Alexander, Etan Orgel, Nicole J Ullrich, Zach Prudowsky and 2 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Willem H CollierDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-1091-2567
Mark ZobeckDepartment of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.
Adam J EsbenshadeDivision of Pediatric Hematology-Oncology, Vanderbilt-Ingram Cancer Center, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
Christopher C DvorakDivision of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-6146-3952
Lillian SungDivision of Haematology-Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0951-3091
David FreyerKeck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-5280-990X
Sarah AlexanderDivision of Haematology-Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Etan OrgelKeck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-1487-6818
Nicole J UllrichDepartment of Neurology, Boston Children's Hospital and Dana-Farber Cancer and Blood Disorders Center, Harvard University, Boston, Massachusetts, USA.
Zach PrudowskyDepartment of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-3789-1121
Brian FisherDepartments of Pediatrics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8224-4281
Caitlin W ElgartenDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-2474-3031

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Understanding longitudinal microbiome change in relation to immunologic outcomes in pediatric SCT recipients.K23HL161309 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Caitlin Walfoort Elgarten · 2022 to 2026
$907k
NCI NIH HHS U10 CA180886NCI NIH HHS UG1 CA189955NHLBI Career Development Award K23HL161309NHLBI NIH HHS K23 HL161309The COG National Cancer Institute Community Oncology Research Program (NCORP) Research Base Grant UG1CA189955The COG NCTN Operations Center Grant U10CA180886
6 · The paper itself

Abstract

Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance. We performed post hoc analyses using HCE in two randomized trials conducted by the Children's Oncology Group. We found that HCE can be more sensitive overall endpoints for detecting treatment benefit as well as found that HCE can support harmonized trial conclusions in the presence of intervention benefits and harms. These analyses illustrate the potential of HCE to improve the interpretability of complex pediatric supportive care trials and support consideration of their prospective use.

Indexed as

Endpoint DeterminationNeoplasmsChildHumanshierarchical composite endpointsrandomized clinical trialssupportive care

Identifiers

PMID42499270
PMCPMC13487803

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.